Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-synuclein + amyloid-beta combined immunotherapy
- Development stage
- Preclinical
- Lead developer
- AC Immune
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Alpha-synuclein + amyloid-beta combined immunotherapy is a preclinical active vaccine candidate developed by Affiris for the treatment of neurodegenerative diseases characterized by mixed protein pathology, specifically Dementia with Lewy Bodies (DLB). The therapy utilizes Affiris's proprietary Specific Active ImmunoTherapy (SAIT) platform and AFFITOME technology to present synthetic peptides (AFFITOPEs) that mimic the epitopes of both alpha-synuclein and amyloid-beta. This dual-targeting approach is designed to stimulate the patient's immune system to produce specific antibodies that target and clear pathological aggregates of both proteins, potentially addressing the synergistic toxicity observed in DLB and related synucleinopathies.
- Other names
- combined SAIT-based vaccinationalpha-synuclein and amyloid-beta vaccine
02
Targets
Amyloid-beta aggregate (N-terminal epitope)aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on alpha-synuclein + amyloid-beta combined immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-synuclein + amyloid-beta combined immunotherapy.